Sutro Biopharma is undergoing a seismic shake-up—jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash. The almost 50% layoffs ...

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

Nationalist Congress Party (NCP) leader and Maharashtra Minister Babasaheb Mohanrao Patil expressed his view that party chief Ajit Pawar has the potential to become Chief Minister and in the ...

Revenue: US$62.0m (down 60% from FY 2023). Net loss: US$227.5m (loss widened by 113% from FY 2023). US$2.96 loss per share (further deteriorated from US$1.78 loss in FY 2023). Revenue exceeded ...

Jane Chung has replaced Bill Newell as Sutro's CEO. Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its attention to a trio of ...

Oppenheimer downgraded Sutro Biopharma (STRO) to Perform from Outperform. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses.

NASDAQ:STRO opened at $0.81 on Friday. Sutro Biopharma has a 12 month low of $0.81 and a 12 month high of $6.13. The firm has a market capitalization of $66.80 million, a PE ratio of -0.50 and a ...

Piper Sandler downgraded Sutro Biopharma (STRO) to Neutral from Overweight with a price target of $2, down from $8. The company is deprioritizing development of luvelta in order to focus resources ...

Sutro Biopharma’s 2024 revenue fell to $62 million from $153.7 million in 2023. The company expects its cash runway to last through at least Q4 2026, excluding potential milestone payments. The ...

By 2026 Sutro also intends to progress its integrin beta-6 ADC, STRO-006, into clinical development and submit an IND for its first fully owned dual-payload ADC in 2027.By year-end, the firm will ...

Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The company had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10 ...

(RTTNews) - Sutro Biopharma Inc. (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRaME-O1 trial with luveltamab tazevibulin (luvelta ...